Markets:

Overview

News

Currencies

International

Treasuries

Alkermes plc - Ordinary Shares (NQ:ALKS)

28.61 +0.42 (+1.49%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alkermes plc - Ordinary Shares

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Best Stocks To Buy Now: June 02, 2022

June 02, 2022

The stock market continues to be one of the best ways for regular investors to build wealth over time. The

Via Best Stocks

Topics Artificial Intelligence Cannabis

Sarissa Condemns Poor Corporate Governance at Alkermes

May 27, 2022

From Sarissa Capital Management LP

Via Business Wire

New Findings About Life With Bipolar 1 Disorder

May 27, 2022

SOURCE: Alkermes

Via 3BL Media

Global Central Nervous System Treatment Market Is Expected to Reach $166 Billion In 2028

May 26, 2022

Palm Beach, FL – May 26, 2022 – FinancialNewsMedia.com News Commentary – Worldwide, there is a rapid increase in the prevalence and incidence of neurological disorders such as multiple sclerosis,...

Via FinancialNewsMedia

Recap: Alkermes Q1 Earnings ↗

April 27, 2022

Alkermes (NASDAQ:ALKS) reported its Q1 earnings results on Wednesday, April 27, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Treating Bipolar 1 Disorder

May 24, 2022

SOURCE: Alkermes

Via 3BL Media

Top Biotech Stocks: Trading Opportunities For Next Week - Sunday, May 22 ↗

May 22, 2022

A security pattern traces the distinct movements of security prices that, once recognized, help traders to make informed trading decisions. Let's look at some biotech stock opportunities by analyzing...

Via Talk Markets

Alkermes Awarded 2022 Platinum Bell Seal for Workplace Mental Health

May 19, 2022

SOURCE: Alkermes

Via 3BL Media

Tips to Improve Mental Well-Being

May 17, 2022

SOURCE: Alkermes

Via 3BL Media

Alkermes Celebrates National Women's Health Week by Reminding You Why Regular Cancer Screenings Are Vital

May 13, 2022

SOURCE: Alkermes

Via 3BL Media

Expert Ratings for Alkermes ↗

April 21, 2022

Alkermes (NASDAQ:ALKS) has observed the following analyst ratings within the last quarter:

Via Benzinga

Alkermes to Highlight Data Related to Psychiatry Portfolio at Upcoming Scientific Conferences During Mental Health Awareness Month

May 06, 2022

SOURCE: Alkermes

Via 3BL Media

Looking Into Alkermes's Return On Capital Employed ↗

April 28, 2022

Benzinga Pro data, Alkermes (NASDAQ:ALKS) reported Q1 sales of $278.55 million. Earnings fell to a loss of $35.90 million, resulting in a 4212.6% decrease from last quarter.

Via Benzinga

61 Biggest Movers From Yesterday ↗

April 28, 2022

Gainers Vivakor, Inc. (NASDAQ: VIVK) shares jumped 113.5% to close at $3.65 on Wednesday after the company announced it has signed a 10-year contract with Hot Oil Transport with...

Via Benzinga

38 Stocks Moving In Wednesday's Mid-Day Session ↗

April 27, 2022

Gainers Vivakor, Inc. (NASDAQ: VIVK) gained 154% to $4.3550 after the company announced it has signed a 10-year contract with Hot Oil Transport with a potential value of...

Via Benzinga

LGBTQ+ People Are More Likely to Experience a Mental Health Condition

April 27, 2022

SOURCE: Alkermes

Via 3BL Media

Topics LGBTQ

The Daily Biotech Pulse: Molecular Partners Plunges On Double Bad News, Pfizer/BioNTech Seek Nod For COVID-19 Shot In Kids, Pfizer Invests In Zentalis ↗

April 27, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Alkermes's Earnings Outlook ↗

April 26, 2022

Alkermes (NASDAQ:ALKS) is set to give its latest quarterly earnings report on Wednesday, 2022-04-27. Here's what investors need to know before the announcement. Analysts estimate that Alkermes will...

Via Benzinga

The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More ↗

April 24, 2022

Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering...

Via Benzinga

Alkermes Earnings Conference Call Is Coming Up, Here's What You Need To Know ↗

April 22, 2022

Alkermes (NASDAQ:ALKS) will host a conference call at 08:00 AM ET on April 27, 2022, to discuss Q1 2022 earnings results. How to Attend Alkermes (ALKS) Conference Call Follow this link to access the...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For April 20, 2022 ↗

April 20, 2022

Upgrades

Via Benzinga

Alkermes Starts Arbitration Related to NanoCrystal Tech Agreements With Janssen ↗

April 19, 2022

Via Benzinga

This Biotech Company Is Landing Ketamine-Assisted Therapy In England's Capital ↗

March 31, 2022

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. As it pushes ahead with expansion into the United States,...

Via Benzinga

This Ketamine-Assisted Therapy Company Is Developing New Ways To Treat Alcohol Addiction ↗

March 24, 2022

Picture credit: Martin Sanchez on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice.

Via Benzinga

The Daily Biotech Pulse: Moderna Files For 2nd COVID Booster Shot Authorization, Lexicon Secures Debt Funding, Amneal Gets Sub-License to Manufacture Generic COVID Pill ↗

March 18, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

Nektar Therapeutics Loses Half Its Value As Bristol Myers-Paired Melanoma Test Flops ↗

March 14, 2022

Sentiment was low heading into the study and analysts aren't hopeful for other tests.

Via Investor's Business Daily

The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings ↗

March 13, 2022

Biotech stocks pulled back for a second week running, as the Ukraine war cast its cloud on the broader market. Dwindling earnings news flow and company-specific developments...

Via Benzinga

Rising Number of Mental Health Disorders Fuel Advancing Initiatives to Reduce Psychiatric and Neurological Conditions

March 08, 2022

Palm Beach, FL –– March 8, 2022 – FinancialNewsMedia.com News Commentary – According to a report from Grand View Research “High unmet medical needs and government initiatives to reduce the psychiatric...

Via FinancialNewsMedia

Topics Economy

The Ruble Is Rubble ↗

March 03, 2022

MSCI says Russian companies are

Via Talk Markets

Alkermes' Nemvaleukin Shows Encouraging Anti-Tumor Activity In Pretreated Kidney Cancer ↗

February 17, 2022

Alkermes plc (NASDAQ: ALKS) presented new data from the ongoing phase 1/2 ARTISTRY-1 trial for nemvaleukin alfa, engineered interleukin-2 (IL-2) variant...

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Alkermes plc - Ordinary Shares (NQ:ALKS)

All News about Alkermes plc - Ordinary Shares

Starting at $3.75/week.

Subscribe Today